Metolazone 1 mg/mL Oral Suspension is a liquid dosage form where the active ingredient, Metolazone, is uniformly dispersed throughout a liquid medium, ensuring a homogeneous mixture for precise administration. This formulation is primarily used to treat hypertension and edema associated with congestive heart failure or renal disorders.

Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Metolazone 1 mg/mL Oral Suspension is a liquid formulation of the diuretic medication metolazone, designed to facilitate precise dosing and ease of administration. This suspension provides a homogeneous mixture where metolazone is uniformly dispersed throughout the liquid medium, ensuring consistent delivery of the active ingredient with each dose.
Metolazone is a thiazide-like diuretic that works by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys. This action promotes the excretion of sodium and water, which helps reduce fluid overload and decrease blood pressure. It is commonly used in the management of conditions such as edema associated with congestive heart failure, renal dysfunction (including nephrotic syndrome), and hypertension.
For patients, the oral suspension form offers an alternative to tablets, particularly beneficial for those who have difficulty swallowing pills or require individualized dosing adjustments. The liquid form allows for more precise titration of dosages, which can be crucial in managing fluid balance and blood pressure effectively. Accurate dosing is essential to minimize the risk of electrolyte imbalances and other potential side effects.
Prescribers may find the 1 mg/mL suspension advantageous when standard tablet strengths do not align with the patient’s specific dosing needs. The flexibility of adjusting the dose in small increments can improve therapeutic outcomes and enhance patient compliance. Additionally, the liquid form ensures that patients receive a consistent dose, as it eliminates issues related to tablet splitting or crushing, which can lead to dosage inaccuracies.
Patients should be aware of the importance of adhering to their prescribed dosing schedule and the necessity of regular monitoring. Metolazone can cause electrolyte disturbances such as hypokalemia, hyponatremia, and hypomagnesemia, so periodic blood tests may be required to monitor electrolyte levels and renal function. Patients should report any symptoms such as muscle weakness, irregular heartbeat, extreme thirst, or confusion to their healthcare provider promptly.
Before initiating therapy with Metolazone Oral Suspension, prescribers should consider contraindications such as hypersensitivity to metolazone or sulfonamide-derived drugs, anuria, hepatic coma, or severe renal impairment. Caution is advised when prescribing to patients with conditions like gout, diabetes mellitus, or systemic lupus erythematosus, as metolazone may exacerbate these conditions.
Administration instructions for the oral suspension should be followed carefully. Patients or caregivers should shake the bottle well before each use to ensure the medication is evenly dispersed. Dosing should be measured accurately using an oral syringe or dosing spoon provided by the pharmacy to maintain precise control over the amount administered.
If you have any questions about Metolazone 1 mg/mL Oral Suspension or need further information regarding its use, please reach out to us for assistance.
Metolazone is a thiazide-like diuretic commonly used to treat conditions such as hypertension and edema associated with congestive heart failure or renal disorders. When formulated as a 1 mg/mL oral suspension, it provides a convenient liquid dosage form for patients who may have difficulty swallowing tablets or require precise dosing adjustments. However, like all medications, metolazone can interact with other drugs, potentially altering its effectiveness or increasing the risk of adverse effects.
One of the primary concerns with metolazone is its potential to interact with other antihypertensive agents. When used concomitantly with other diuretics, ACE inhibitors, or angiotensin II receptor blockers, there is an increased risk of hypotension and electrolyte imbalances, particularly hypokalemia. Patients should be monitored closely for signs of low blood pressure and electrolyte disturbances, and dose adjustments may be necessary.
Nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the diuretic and antihypertensive effects of metolazone. This interaction is due to NSAIDs' ability to inhibit renal prostaglandin synthesis, which can lead to sodium and water retention. Patients using NSAIDs concurrently with metolazone should be monitored for diminished therapeutic effects and potential worsening of edema or hypertension.
Metolazone can also interact with lithium, leading to increased serum lithium levels and a higher risk of lithium toxicity. This occurs because diuretics can reduce the renal clearance of lithium. Patients on lithium therapy should have their lithium levels monitored closely, and adjustments to the lithium dosage may be required to avoid toxicity.
Additionally, metolazone may enhance the effects of other medications that prolong the QT interval, such as certain antiarrhythmics, antipsychotics, and antibiotics. This can increase the risk of serious cardiac arrhythmias. Patients should be monitored for signs of QT prolongation, and alternative therapies should be considered if necessary.
Patients taking metolazone should also be cautious with the use of corticosteroids or adrenocorticotropic hormone (ACTH), as these can exacerbate the risk of hypokalemia. Regular monitoring of potassium levels is recommended, and potassium supplements or dietary modifications may be necessary to maintain appropriate potassium levels.
For both patients and prescribers, it is crucial to review all current medications, including over-the-counter drugs and supplements, to identify potential interactions with metolazone. This proactive approach can help mitigate risks and ensure the safe and appropriate use of metolazone oral suspension. If you have any questions or need further information, please reach out to us at Bayview Pharmacy.
Metolazone 1 mg/mL Oral Suspension is a liquid dosage form designed to provide a uniform dispersion of the active ingredient, metolazone, throughout a liquid medium. This formulation ensures a homogeneous mixture, allowing for precise dosing and ease of administration, particularly beneficial for patients who may have difficulty swallowing tablets or require tailored dosing adjustments. The liquid suspension facilitates rapid absorption of metolazone in the gastrointestinal tract, leading to effective therapeutic outcomes.
Metolazone is a thiazide-like diuretic that works primarily by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys. This action results in increased excretion of sodium and water, along with potassium and hydrogen ions, which helps to reduce fluid accumulation in the body. By promoting diuresis, metolazone effectively decreases blood volume, leading to a reduction in blood pressure and alleviation of symptoms associated with fluid overload conditions.
This formulation is particularly useful in the management of conditions such as hypertension and edema associated with congestive heart failure, renal dysfunction, or hepatic cirrhosis. In patients with hypertension, metolazone helps to lower blood pressure, thereby reducing the risk of cardiovascular events such as stroke and heart attack. For those experiencing edema, the diuretic effect of metolazone aids in the reduction of swelling and fluid retention, improving overall comfort and quality of life.
For prescribers, the 1 mg/mL concentration allows for flexible dosing regimens, enabling precise titration to achieve optimal therapeutic effects while minimizing potential side effects. The liquid suspension form is particularly advantageous for pediatric patients, elderly individuals, or those with swallowing difficulties, ensuring adherence to prescribed treatment plans.
Patients should be advised to take the suspension as directed by their healthcare provider, and to report any unusual symptoms or side effects. Regular monitoring of electrolytes and kidney function may be necessary to ensure safe and appropriate use of metolazone, as it can lead to electrolyte imbalances or renal impairment if not properly managed.
If you have any questions or require further information about Metolazone 1 mg/mL Oral Suspension, please reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is here to assist you with any inquiries or concerns you may have regarding this formulation.
Metolazone 1 mg/mL Oral Suspension is a liquid dosage form where Metolazone is uniformly dispersed in a liquid medium, creating a homogeneous mixture for easy administration.
Store the suspension at room temperature, away from direct sunlight and moisture. Ensure the bottle is tightly closed when not in use. Do not freeze the suspension.
Shake the bottle well before each use to ensure the medication is evenly distributed. Use a proper measuring device to ensure accurate dosing as prescribed by your healthcare provider.
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose to catch up.
Metolazone can be taken with or without food. However, it is best to follow your healthcare provider's instructions regarding food intake.
Common side effects may include dizziness, headache, or gastrointestinal disturbances. If you experience severe side effects such as allergic reactions, contact your healthcare provider immediately.
The safety and effectiveness of Metolazone in children have not been established. Consult your healthcare provider for advice specific to pediatric use.
Consult your healthcare provider before using Metolazone if you are pregnant or breastfeeding, as it may not be recommended depending on your specific circumstances.
In case of an overdose, seek immediate medical attention or contact a poison control center. Symptoms of overdose may include severe dizziness, fainting, or electrolyte imbalance.
Yes, Metolazone can interact with other medications. Inform your healthcare provider about all the medications and supplements you are taking to avoid potential interactions.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally